Thinly traded nano cap BrainStorm Cell Therapeutics (BCLI +1.4%) is up on below-average volume in reaction to the issuance of a new U.S. patent covering its NurOwn cell therapy.
The patent, entitled “Method of Qualifying Cells,” covers a pharmaceutical composition for MSC-NTF cells secreting neurotrophic factors (NurOwn) consisting of a culture medium as a carrier and an isolated population of differentiated bone marrow-derived mesenchymal stem cells (MSCs) that secrete neurotrophic factors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.